Journal
PHYTOTHERAPY RESEARCH
Volume 35, Issue 9, Pages 5154-5162Publisher
WILEY
DOI: 10.1002/ptr.7184
Keywords
antischistosomal activity; licarin A; lignan; Nectandra oppositifolia; schistosoma; schistosomiasis
Categories
Funding
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/PNPD) [88887.351532/ 2019-00]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/22488-3, 2018/07885-1, 2019/25289-0, 2019/25905-2]
Ask authors/readers for more resources
Schistosomiasis is a widespread human parasitic disease affecting over 200 million people, with praziquantel as the main chemotherapy. Studies show that licarin A (LIC-A) has potential antiparasitic activity against Schistosoma mansoni. LIC-A demonstrated partial cure in infected mice and moderate inhibition of parasite eggs, supporting its potential as a novel antischistosomal agent.
Schistosomiasis is a widespread human parasitic disease currently affecting over 200 million people, particularly in poor communities. Chemotherapy for schistosomiasis relies exclusively on praziquantel (PZQ). Previous studies have shown that licarin A (LIC-A), a dihydrobenzofuran neolignan, exhibited in vitro antiparasitic activity against Schistosoma mansoni adult worms. This study aimed to investigate the potential of LIC-A, isolated as main metabolite from leaves of Nectandra oppositifolia Nees & Mart. (Lauraceae), as an antischistosomal agent orally active in schistosomiasis animal model. PZQ was used as a reference compound. As result, LIC-A showed, at a single dose of 400 mg/kg, to be able to partially cure infected mice (worm burden reductions of similar to 50%). Parasite eggs, that are responsible for a variety of pathologies and transmission of schistosomiasis, were also moderately inhibited by LIC-A (egg burden reductions of similar to 50%-60%). Furthermore, it was observed that LIC-A achieved a slight reduction of hepatomegaly and splenomegaly. Collectively, although LIC-A was partially active when administered orally, these results give support for the antiparasitic potential LIC-A as lead compound for novel antischistosomal agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available